Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–66.

Article  CAS  PubMed  Google Scholar 

Writing C, Kittleson MM, Ruberg FL, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81:1076–126.

Article  Google Scholar 

Rossi M, Varra GG, Porcari A, et al. Re-definition of the epidemiology of cardiac amyloidosis. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10071566.

Article  PubMed  PubMed Central  Google Scholar 

Stehlik B, Sideris K, Brinker L, Waldron J, Carter S. Wild-type transthyretin amyloidosis: a prevalent and underdiagnosed cause of heart failure with preserved ejection fraction. Cureus. 2024;16:e62623.

PubMed  PubMed Central  Google Scholar 

Stern LK, Grodin JL, Maurer MS, et al. The cardiac amyloidosis registry study (CARS): rationale, design and methodology. J Card Fail. 2024;30:669–78.

Article  PubMed  Google Scholar 

Shinzato K, Takahashi Y, Yamaguchi T, et al. Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Eur Heart J. 2025. https://doi.org/10.1093/eurheartj/ehaf332.

Article  PubMed  PubMed Central  Google Scholar 

Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023;20:361–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Correction to. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2023;147:e674.

Google Scholar 

Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000;130:88–98.

Article  CAS  PubMed  Google Scholar 

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;73:2872–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27:217–22.

Article  CAS  PubMed  Google Scholar 

Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac Amyloidosis-associated heart failure hospitalizations among Fee-for-Service medicare beneficiaries in the united States. Circ Heart Fail. 2019;12:e005407.

Article  PubMed  PubMed Central  Google Scholar 

AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267–74.

Article  PubMed  Google Scholar 

Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24:2342–51.

Article  CAS  PubMed  Google Scholar 

Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87.

Article  PubMed  PubMed Central  Google Scholar 

Damy T, Costes B, Hagege AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826–34.

Article  PubMed  Google Scholar 

Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC: Heart Failure. 2020;8:712–24.

PubMed  Google Scholar 

Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2.

Article  PubMed  Google Scholar 

Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368–83.

Article  PubMed  Google Scholar 

Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–20.

Article  PubMed  Google Scholar 

Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6:1118–27.

Article  PubMed  Google Scholar 

Sinigiani G, De Michieli L, Porcari A, et al. Atrial electrofunctional predictors of incident atrial fibrillation in cardiac amyloidosis. Heart Rhythm. 2024;21:725–32.

Article  PubMed  Google Scholar 

Stollberger C, Gatterer E, Finsterer J. Central and peripheral vagal nerve involvement in atrial fibrillation. Eur Heart J. 2009;30:1012.

Article  PubMed  Google Scholar 

Bazoukis G, Saplaouras A, Efthymiou P, et al. Atrial fibrillation in the setting of cardiac amyloidosis - a review of the literature. J Cardiol. 2024;84:155–60.

Article  PubMed  Google Scholar 

Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: a systematic review and meta-analysis. Int J Cardiol. 2024;402:131813.

Article  PubMed  Google Scholar 

Ioannou A, Massa P, Patel RK, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44:2893–907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285–8.

Article  CAS  PubMed  Google Scholar 

Petzl AM, Oranefo J, Oraii A, et al. Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias. Heart Rhythm O. 2025;2:6:1088–96.

Article  Google Scholar 

Martens P, Hanna M, Valent J, et al. Electrical dyssynchrony in cardiac amyloidosis: Prevalence, predictors, clinical correlates, and outcomes. J Card Fail. 2022;28:1664–72.

Article  PubMed  Google Scholar 

Lellouche N, Defaye P, Algalarrondo V, et al. Management of conduction disease and arrhythmias in patients with cardiac amyloidosis: a position paper from the working group of cardiac pacing and electrophysiology of the French society of cardiology. Arch Cardiovasc Dis. 2025;118:63–74.

Article  PubMed  Google Scholar 

Monte IP, Faro DC, Trimarchi G, et al. Left atrial strain imaging by speckle tracking echocardiography: the supportive diagnostic value in cardiac amyloidosis and hypertrophic cardiomyopathy. J Cardiovasc Dev Dis. 2023. https://doi.org/10.3390/jcdd10060261.

Article  PubMed  PubMed Central  Google Scholar 

Martens P, Bhattacharya S, Longinow J, et al. Hemodynamic profiling and prognosis in cardiac amyloidosis. Circ Heart Fail. 2023;16:e010078.

Article  CAS  PubMed  Google Scholar 

Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119:2490–7.

Article  CAS  PubMed  Google Scholar 

Yang Z, Subati T, Kim K, et al. Natriuretic peptide oligomers cause proarrhythmic metabolic and electrophysiological effects in atrial myocytes. Circulation: Arrhythmia and Electrophysiology. 2022;15:e010636.

CAS  PubMed